AbbVie today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the ...
AbbVie today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with ...
Harald Otto Steinum, specialist in infectious diseases and senior consultant in the Department of Infectious Diseases, St Olav's Hospital, Trondheim University Hospital. The author has completed the ...
HSV type 1 reactivation was prevalent among critically ill patients with COVID-19 and was independently associated with ...
WHO estimates 3.8 billion people carry herpes, most unknowingly. Experts say awareness, safe sex and antiviral treatment help ...
ABL Diagnostics (Euronext Paris – Compartiment B – ISIN: FR001400AHX6), a company specialized in molecular diagnostic solutions for infectious diseases, announces the commercial availability of ...
64 percent of people under 50 have HSV-1 – WHO’s report breaks down herpes symptoms, prevention, treatment, and why stigma is ...
TAMPA, FL / ACCESS Newswire / July 31, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) (“DataMeds AI” or the “Company”), a Health IT company leveraging its artificial intelligence platform EinsteinRx ™ and ...
If you’ve had a cold sore before, you may have noticed they usually return in the same spot. That’s because cold sores are ...
Health experts say that for many people, the psychological impact of a genital herpes diagnosis - which is treatable but not ...
IGNYTE showed that patients with confirmed progression on an anti-PD-1-based regimen who received RP1 plus nivolumab had a 34% response rate, with a median duration of 24.8 months, and 15% of them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results